FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) (Influenza A Virus A/Idaho/07/2018 (H1n1) Antigen (Mdck Cell Derived, Propiolactone Inactivated, Influenza A Virus A/Indiana/08/2018 (H3n2) Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/Singapore/Inftt-16-0610/2016 Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/Iowa/06/2017 Antigen (Mdck Cell Derived, Propiolactone Inactivated)) Injection, Suspension FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) (Influenza A Virus A/Idaho/07/2018 (H1n1) Antigen (Mdck Cell Derived, Propiolactone Inactivated, Influenza A Virus A/Indiana/08/2018 (H3n2) Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/Singapore/Inftt-16-0610/2016 Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza B Virus B/Iowa/06/2017 Antigen (Mdck Cell Derived, Propiolactone Inactivated)) Injection, Suspension [Seqirus, Inc.]

Updated Date: Jul 29, 2019 EST

from
https://fda.report/DailyMed/40406cf8-a2ae-4159-a8a5-5d02e5c6c7bc